

must be received at the Reserve Bank indicated for the application or the offices of the Board of Governors not later than May 30, 1995.

A. Federal Reserve Bank of Cleveland (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Mellon Bank Corporation*, Pittsburgh, Pennsylvania; to acquire Certus Financial Corporation, San Francisco, California, and thereby engage in providing investment and advisory services, pursuant to § 225.25(b)(4) of the Board's Regulation Y.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Mountain Bancshares, Inc.*, Yellville, Arkansas; to acquire Financial Institution Services, Inc., Green Forest, Arkansas, and thereby engage in data processing and data transmission services for financial institutions, pursuant to § 225.25(b)(7) of the Board's Regulation Y. The geographic scope for these activities is the cities of Yellville, Bull Shoals, and Flippin, Arkansas.

Board of Governors of the Federal Reserve System, May 10, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-11999 Filed 5-15-95; 8:45 am]

BILLING CODE 6210-01-F

Larry F. Ness, et al.; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies; Correction

This notice corrects the notices (FR Doc. 95-11227) published on page 22580 of the issue for Monday, May 8, 1995.

Under the Federal Reserve Bank of Minneapolis heading, the entry for Larry F. Ness, is revised to read as follows:

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Larry F. Ness*, Yankton, South Dakota; to acquire an additional 26.39 percent, for a total of 45.78 percent, of the voting shares of First Dakota Financial Corporation, Yankton, South Dakota, and thereby indirectly acquire First Dakota National Bank, Yankton, South Dakota.

Under the Federal Reserve Bank of San Francisco heading, the entry for John C. Bell, is revised to read as follows:

B. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. *John C. Bell; John C. Bell Family Trust and K&G Trust*, all of Studio City, California; to acquire an additional 4.68 percent, for a total of 13.73 percent, of the voting shares of Western Security Bancorp, Burbank, California, and thereby indirectly acquire Western Security Bank, N.A., Burbank, California.

Comments on these applications must be received by May 22, 1995.

Board of Governors of the Federal Reserve System, May 10, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-12000 Filed 5-15-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Endocrinologic and Metabolic Drugs Advisory Committee

Date, time, and place. June 1, 1995, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, FAX 301-443-0699, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in endocrine and metabolic disorders.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before May 26, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will hear presentations and discuss data submitted regarding the safety and efficacy of acarbose, new drug application 20-482, (Precose®, Bayer Corp.), for a non-insulin dependent diabetes mellitus indication.

Working Group Meeting of the Food Advisory Committee

Date, time, and place. June 7 and 8, 1995, 8:30 a.m., Days Inn—Downtown Convention Center, 1201 K St. NW., Washington, DC.

Type of meeting and contact person. Open working group discussion, June 7, 1995, 8:30 a.m. to 4 p.m.; open public hearing, 4 p.m. to 5:30 p.m., unless public participation does not last that long; open working group discussion, June 8, 1995, 8:30 a.m. to 12 m.; Lynn A. Larsen, Center for Food Safety and Applied Nutrition (HFS-5), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4727, or Catherine M. DeRoever, Advisory Committee Staff (HFS-22), 202-205-4251, FAX 202-205-4970, or FDA

Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Food Advisory Committee, code 10564.

General function of the committee. The committee provides advice on emerging food safety, food science, and nutrition issues that FDA considers of primary importance in the next decade.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before May 31, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. If necessary, comments may be limited to 5 minutes.

Open working group discussion. The working group will consider whether foods containing substances that may cause serious adverse gastrointestinal effects, such as laxation, present a significant concern such that consumer education or special labeling for these foods would be appropriate options for FDA to pursue. More detailed information regarding the meeting agenda that may become available prior to the meeting will be provided to the public via the 800 number given above.

Food Advisory Committee

Date, time, and place. June 8, 1995, 1 p.m., and June 9, 1995, 8:30 a.m., Days Inn—Downtown Convention Center, 1201 K St. NW., Washington, DC.

Type of meeting and contact person. Open committee discussion, June 8, 1995, 1 p.m. to 4 p.m.; open public hearing, 4 p.m. to 5 p.m., unless public participation does not last that long; open committee discussion, June 9, 1995, 8:30 a.m. to 4 p.m.; Lynn A. Larsen, Center for Food Safety and Applied Nutrition (HFS-5), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4727, or Catherine M. DeRoever, Advisory Committee Staff (HFS-22), 202-205-4251, FAX 202-205-4970, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Food Advisory Committee, code 10564.

General function of the committee. The committee provides advice on emerging food safety, food science, and nutrition issues that FDA considers of primary importance in the next decade.

Agenda—Open public hearing. Interested persons may present data,

information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before May 31, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. If necessary, comments may be limited to 5 minutes.

Open committee discussion. The committee will consider the actions and recommendations of two special working groups regarding: (1) An educational campaign on *Vibrio vulnificus*, and (2) certain food products that may cause unexpected gastrointestinal effects. The committee will also discuss with FDA staff, future food safety strategies for the agency. More detailed information regarding the meeting agenda that may become available prior to the meeting will be provided to the public via the 800 number given above.

National Task Force on AIDS Drug Development

Date, time, and place. June 29, 1995, 9 a.m., and June 30, 1995, 8:30 a.m., Omni Shoreham Hotel, Diplomat Room, 250 Calvert St. NW., Washington, DC.

Type of meeting and contact person. Open task force discussion, June 29, 1995, 9 a.m. to 4:30 p.m.; open public hearing, 4:30 p.m. to 5:30 p.m., unless public participation does not last that long; open task force discussion, June 30, 1995, 8:30 a.m. to 11:30 a.m.; Heidi C. Marchand or Kimberley M. Miles, Office of AIDS and Special Health Issues (HF-12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-0104, or the FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), National Task Force on AIDS Drug Development, code 12602.

General function of the task force. The task force shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.

Open task force discussion. The task force will meet to discuss incentives and disincentives for private investment and collaboration in drug discovery and development for HIV/acquired immune deficiency syndrome (AIDS).

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the task force. Those desiring to make formal presentations should notify the contact person before June 5, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does

not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HF1-35), Food and Drug Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: May 10, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95-12019 Filed 5-15-95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Availability of Funds for the Community Scholarship Programs

AGENCY: Health Resources and Services Administration, PHS.

ACTION: Notice of availability of funds.

SUMMARY: The Health Resources and Services Administration (HRSA) announces the availability of approximately \$100,000 under section 338L of the Public Health Service (PHS) Act for competing Grants to States for Community Scholarship Programs.

The purpose of the Community Scholarship Program (CSP) is to enable States to increase the availability of primary health care in urban and rural federally designated health professional shortage areas (HPSAs) by assisting community organizations to provide scholarships for the education of

individuals to serve as health professionals in these communities.

The PHS is committed to achieving the health promotion and disease prevention objectives of *Healthy People 2000*, a PHS-led national activity. This grant program is related to the objectives of improving access to and availability of primary health care services for all Americans, especially the underserved populations. Potential applicants may obtain a copy of *Healthy People 2000* (Full Report: Stock No. 017-001-00474-0) or *Healthy People 2000* (Summary Report; Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone number 202-783-3238).

Pub. L. 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities in which education, library, day care, regular and routine health care and early childhood development services are provided to children. Smoking must also be prohibited in indoor facilities that are constructed, operated or maintained with Federal funds.

DUE DATES: Applications are due June 15, 1995. Applications will be considered to have met the deadline if they are (1) received on or before the deadline date; or (2) postmarked on or before the established deadline date and received in time for orderly processing. Applicants should request a legibly dated U.S. Postal Service postmark or obtain a receipt from a commercial carrier. Private metered postmarks will not be acceptable as proof of timely mailing. Late applications not accepted for processing will be returned to the applicant.

ADDRESSES: Application materials may be obtained from, and completed applications should be returned to: Ms. Alice H. Thomas, Grants Management Officer, Bureau of Primary Health Care (BPHC), 4350 East-West Highway, 11th Floor, Bethesda, Maryland 20814, (301) 594-4250. The Grants Management staff is available to provide assistance on business management issues. Applications for these grants will be made on PHS Form 5161-1 with revised face sheet DHHS Form 424, as approved by the Office of Management and Budget (OMB) under control number 0937-0189.

FOR FURTHER INFORMATION CONTACT: For general program information and technical assistance, please contact Carolyn Beth Lee, R.N., Division of Scholarships and Loan Repayments, BPHC, HRSA, 4350 East-West Highway, 10th Floor, Bethesda, Maryland 20814, at (301) 594-4370.

SUPPLEMENTARY INFORMATION: In FY 1995 approximately \$100,000 will be awarded for 3-5 new and competing continuation grants ranging from \$5,000 to \$75,000 for a 12-month budget period and up to a 3-year project period. Under this program, States enter into agreements with public or private nonprofit community organizations located in federally designated HPSAs. These organizations will recruit qualified residents of their communities and provide scholarships to them to become physicians, certified nurse practitioners, certified nurse midwives, or physician assistants based on the needs of the communities.

This grant program is intended to be consistent with the efforts of the National Health Service Corps (NHSC) Scholarship Program, NHSC Loan Repayment Program and NHSC State Loan Repayment Program to meet the needs of underserved populations in federally designated HPSAs through the placement of primary care practitioners. For purposes of this program, the term "primary health care" means health services regarding family medicine, general internal medicine, general pediatrics, or obstetrics and gynecology, that are provided by physicians, certified nurse practitioners, certified nurse midwives, or physician assistants. The Secretary is required by statute [Section 338L(l)(3) of the PHS Act] to ensure that, to the extent practicable, not less than 50 percent of the amount appropriated will be in the aggregate expended by the States for making grants to community organizations that are located in rural federally designated HPSAs. Consequently, each State submitting a grant application must submit estimates of the amount of the grant that will be expended regarding the provision of primary health care in urban and rural HPSAs.

Eligibility Requirements

In order for a State to receive a grant under this program, the State must:

1. Receive funding for at least one grant, cooperative agreement, or contract under any provisions of the PHS Act other than section 338L for the fiscal year for which the State is applying;
2. Agree that the grant program will be administered directly by a single State agency;
3. Agree to make grants to community organizations located in federally designated HPSAs in order to assist those community organizations in providing scholarships to individuals enrolled or accepted for enrollment as full-time students in health professions schools accredited by a body or bodies